Johnson & Johnson Announces Opening of London Innovation Centre

Tue Mar 12, 2013 8:00pm EDT

* Reuters is not responsible for the content in this press release.

-- Centre to Serve as European Hub to Accelerate Innovation across the Healthcare
Landscape 

-- Johnson & Johnson Chief Scientific Officer Celebrates Opening at London Expo Keynote 

LONDON, March 13, 2013 /PRNewswire/ -- Johnson & Johnson today announced the opening of
the Johnson & Johnson Innovation centre in London, one of four regional hubs being
established this year in the world's leading innovation hotspots.  A part of Johnson &
Johnson Innovation, the goal of the London innovation centre is to accelerate the best
early stage science in the world and advance the development of new healthcare
solutions.   

"Britain has a worldwide reputation for excellence in innovation - the investment by
Johnson & Johnson here demonstrates this and I am delighted to welcome this new centre
to the UK," says UK Secretary of State for Health Jeremy Hunt, who will be speaking at
the Innovation Expo 2013 on Wednesday.

Johnson & Johnson Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Paul
Stoffels, MD, says, "The London Innovation Centre is part of Johnson & Johnson's broader
innovation strategy to advance human health through collaboration with the world's
leading scientists and entrepreneurs.  We are looking forward to collaborating within
the UK, home to one of the world's thriving life sciences ecosystems." Dr. Stoffels will
address the Expo on Wednesday afternoon. 

The Johnson & Johnson Family of Companies has been investing in the United Kingdom since
1927 and supports directly or indirectly more than 24,000 jobs.  The London Innovation
Centre will be one of more than a dozen facilities of the Johnson & Johnson Family of
Companies in the country.   

Dr. Stoffels underscores Johnson & Johnson's shared commitment with the NHS to address
some of today's most complex and devastating diseases such as Alzheimer's, dementia and
Type 2 diabetes; and emphasizes the need for commitment from the healthcare community to
support emerging companies and entrepreneurs in the UK who are bringing forward new
science and technology.  "Science and technology hold unprecedented opportunities to
transform healthcare, and by investing and collaborating in groundbreaking science we
can deliver transformational innovations in healthcare to people across the world." 

In addition to the new Johnson & Johnson Innovation centre in London, similar facilities
are planned in Boston, San Francisco and, later this year, in Shanghai. Each city was
selected for its robust life sciences community.  

The UK life sciences sector accounts for over 165,000 jobs and over £50 billion in
business.  It is home to a uniquely powerful combination of world-leading universities
and scientific experts; established R&D, manufacturing and supply chain; globally
renowned research charities and the NHS.  This combination of outstanding features makes
London an ideal innovation hub in Europe.

The Johnson & Johnson Innovation centre in London will house science and technology
experts with broad expertise in developing new solutions and products.  The centre will
have local deal-making capabilities to flexibly adapt deal structures to match
early-stage opportunities. This will enable scientists, entrepreneurs and emerging
companies to deliver innovation via collaboration with experts who can drive
partnerships across the pharmaceutical, medical device & diagnostics and consumer
healthcare companies of Johnson & Johnson.

"Our on-the-ground proximity to regional scientists and entrepreneurs will allow us to
build the strong personal relationships that underlie the most successful collaborations
and investment deals," remarked Patrick Verheyen, the head of the Johnson & Johnson
Innovation centre in London.   "At Johnson & Johnson Innovation, we are committed to
ensuring healthcare remains not only a significant source of economic prosperity in the
UK, but also a driving force for improving the health and happiness of people
worldwide." 

Johnson & Johnson Innovation centre in London is located at 1 Chapel Place, London, W1G
OBJ. For more information on the new innovation centres please contact
jnjinnovation@its.jnj.com,[mailto:jnjinnovation@its.jnj.com]. 

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson &
Johnson. We embrace research and science - bringing innovative ideas, products and
services to advance the health and well-being of people. Our approximately 127,600
employees at more than 275 Johnson & Johnson operating companies work with partners in
health care to touch the lives of over a billion people every day throughout the world.

For more information, visit www.jnj.com [http://www.jnj.com/].

About J&J Innovation 

The London innovation centre is part of Johnson & Johnson Innovation, a division of
Johnson & Johnson Finance Corporation, Ltd.  Johnson & Johnson Innovation focuses on
accelerating early innovation and enhancing opportunities for collaboration and
investment across Johnson & Johnson's global healthcare businesses. Johnson & Johnson
Innovation provides scientists, entrepreneurs and emerging companies focused on
early-stage opportunities a one-stop access to science and technology experts who can
facilitate collaborations across the pharmaceutical, medical device and diagnostics and
consumer companies of Johnson & Johnson. Johnson & Johnson Innovation includes local
deal-making capabilities with the flexibility to adapt deal structures to match
early-stage opportunities and establish novel collaborations that speed development of
those innovations to solve unmet needs in patients.  More information can be found here:
www.jnjinnovation.com [http://www.jnjinnovation.com/].

Forward-looking Statements

(This press release contains "forward-looking statements" as defined in the Private
Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these
forward-looking statements. These statements are based on current expectations of future
events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties
materialise, actual results could vary materially from the expectations and projections
of Johnson & Johnson.  Risks and uncertainties include, but are not limited to, general
industry conditions and competition; economic factors, such as interest rate and
currency exchange rate fluctuations; technological advances, new products and patents
attained by competitors; challenges inherent in new product development, including
obtaining regulatory approvals; challenges to patents; changes in behaviour and spending
patterns or financial distress of purchasers of health care products and services;
changes to governmental laws and regulations and domestic and foreign health care
reforms; trends toward health care cost containment; and increased scrutiny of the
health care industry by government agencies.  A further list and description of these
risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's
Annual Report on Form 10-K for the fiscal year ended December 30, 2012.  Copies of this
Form 10-K, as well as subsequent filings, are available online at www.sec.gov,
www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson do not undertake to
update any forward-looking statements as a result of new information or future events or
developments.)


    Contact:


    Media:                                               Investors:

    Seema Kumar                                          Stan Panasewicz

    +1-908-405-1144                                      +1-732-524-2524

    skumar10@its.jnj.com


    Ellen Rose

    +1-650-491-4901

    erose@janimm.com


    Meghan Marschall

    +1-201-323-0578

    mmarscha@its.jnj.com


Johnson & Johnson

Web site:  http://www.jnj.com/
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.